LEXINGTON, Mass., Nov. 8, 2017 /PRNewswire/ -- Agenus Inc.
(NASDAQ: AGEN), an immuno-oncology company with a pipeline of
immune checkpoint antibodies and cancer vaccines, announced today
that Jennifer Buell, Ph.D., Chief
Communications and External Affairs Officer at Agenus, and
Michael Plater, Ph.D., Chief
Business Officer, Agenus, will make a presentation and host one-on
one meetings with investors at the Jefferies Global Healthcare
Conference at the Waldorf Hilton in London, U.K. on Wednesday, November 15, 2017. The Company's
presentation will take place at 8:00 a.m.
GMT.
A live audio webcast will be available on the "Events &
Presentations" section of the Company's investor website at
www.agenusbio.com where a replay will also be available following
the presentation.
About Agenus
Agenus is a clinical-stage immuno-oncology company focused on
the discovery and development of therapies that engage the body's
immune system to fight cancer. The Company's vision is to expand
the patient populations benefiting from cancer immunotherapy by
pursuing a number of combination approaches that leverage a broad
repertoire of antibody therapeutics and proprietary cancer vaccine
platforms. The Company is equipped with a suite of antibody
discovery platforms and a state-of-the-art GMP manufacturing
facility with the capacity to support early phase clinical
programs. Agenus is headquartered in Lexington, MA. For
more information, please visit www.agenusbio.com; information that
may be important to investors will be routinely posted on our
website.
Forward-Looking Statements
This press release contains forward-looking statements that
are made pursuant to the safe harbor provisions of the federal
securities laws, including statements regarding the Company's
planned participation at the Jefferies Global Healthcare conference
in London. These forward-looking
statements are subject to risks and uncertainties that could cause
actual results to differ materially. These risks and uncertainties
include, among others, the factors described under the Risk Factors
section of our most recent Quarterly Report on Form 10-Q or Annual
Report on Form 10-K filed with the Securities and Exchange
Commission. Agenus cautions investors not to place considerable
reliance on the forward-looking statements contained in this
release. These statements speak only as of the date of this press
release, and Agenus undertakes no obligation to update or revise
the statements, other than to the extent required by law. All
forward-looking statements are expressly qualified in their
entirety by this cautionary statement.
Contact:
Agenus Inc.
Jennifer Buell, PhD
781-674-4420
Jennifer.Buell@agenusbio.com
View original content with
multimedia:http://www.prnewswire.com/news-releases/agenus-to-present-at-the-jefferies-global-healthcare-conference-in-london-300552142.html
SOURCE Agenus Inc.